Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 3,931 Cr.
- Current Price ₹ 688
- High / Low ₹ 1,021 / 624
- Stock P/E 49.4
- Book Value ₹ 148
- Dividend Yield 0.29 %
- ROCE 11.6 %
- ROE 11.6 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 373 | 411 | 785 | 859 | 865 | 958 | 1,183 | |
| 322 | 356 | 687 | 760 | 755 | 836 | 1,044 | |
| Operating Profit | 51 | 54 | 99 | 99 | 110 | 122 | 139 |
| OPM % | 14% | 13% | 13% | 11% | 13% | 13% | 12% |
| 1 | 1 | 3 | 9 | 9 | 17 | 17 | |
| Interest | 5 | 4 | 5 | 18 | 14 | 2 | 13 |
| Depreciation | 10 | 6 | 7 | 11 | 11 | 17 | 36 |
| Profit before tax | 38 | 46 | 89 | 78 | 94 | 120 | 107 |
| Tax % | 26% | 26% | 25% | 26% | 27% | 25% | |
| 28 | 34 | 66 | 58 | 68 | 89 | 80 | |
| EPS in Rs | 232.42 | 287.50 | 551.50 | 11.99 | 11.91 | 15.63 | 13.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 7% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 11% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 14% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
| Reserves | 98 | 133 | 199 | 220 | 666 | 756 | 791 |
| 54 | 45 | 176 | 237 | 244 | 329 | 318 | |
| 81 | 178 | 157 | 173 | 187 | 223 | 277 | |
| Total Liabilities | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,443 |
| 73 | 79 | 161 | 161 | 164 | 637 | 653 | |
| CWIP | 0 | 7 | 0 | 22 | 339 | 21 | 7 |
| Investments | 0 | 0 | 60 | 60 | 60 | 60 | 60 |
| 172 | 282 | 322 | 435 | 593 | 647 | 723 | |
| Total Assets | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,443 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 31 | 42 | 58 | 39 | 112 | 20 | |
| -6 | -20 | -188 | -88 | -472 | -100 | |
| -23 | -19 | 125 | 51 | 368 | 84 | |
| Net Cash Flow | 1 | 3 | -5 | 3 | 8 | 4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 85 | 123 | 81 | 98 | 92 | 95 |
| Inventory Days | 84 | 107 | 63 | 67 | 68 | 94 |
| Days Payable | 92 | 132 | 84 | 102 | 111 | 119 |
| Cash Conversion Cycle | 77 | 99 | 60 | 63 | 49 | 70 |
| Working Capital Days | 45 | 39 | 23 | 44 | 58 | 65 |
| ROCE % | 28% | 33% | 21% | 15% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 Feb - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015 Pursuant to Regulation 30 read with Schedule III (Part A) of …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2 Feb - Transcript of the Investor/Analyst Earnings Call held on 27th January, 2026: This is in continuation to our letter dated 27th January, 2026, wherein we had …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2 Feb - Transcript of the Investor/Analyst Earnings Call held on 27th January, 2026: This is in continuation to our letter dated 27th January, 2026, wherein we had …
-
Communication To The Shareholders Of The Company Regarding Deduction Of Tax At Source ('TDS') On Interim Dividend Declared For FY 2025-26.
27 Jan - Interim dividend ₹2/share declared; record date 30 Jan 2026; TDS guidance, submit forms by 30 Jan.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
27 Jan - Audio recording of Innova Captab earnings call for quarter/nine months ended 31-Dec-2025 (27-Jan-2026, 12:00 IST).
Concalls
-
Feb 2026TranscriptPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain